CUPERTINO, Calif., Sept. 7, 2010 (GLOBE NEWSWIRE) -- DURECT Corporation (Nasdaq:DRRX) announced today that management is scheduled to present at three upcoming healthcare conferences.
- Joe Stauffer, Chief Medical Officer and EVP-Corporate Strategy, will deliver a talk entitled "FDA Regulations and Testing for Pain Products" at the National Conference on Pain for Frontline Practitioners in Las Vegas, Nevada on Wednesday, September 8 at 2:30 p.m. Pacific Time.
- Matt Hogan, Chief Financial Officer, will present at the Rodman & Renshaw Life Sciences Conference in New York on Tuesday, September 14 at 10:50 a.m. Eastern Time. A live audio webcast of the presentation will be available by accessing http://www.wsw.com/webcast/rrshq18/drrx.
- Matt Hogan will also present at the UBS Global Life Sciences Conference in New York on Monday, September 20 at 8:00 a.m. Eastern Time. A live audio webcast of the presentation will be available by accessing DURECT's homepage at http://www.durect.com and clicking "Investor Relations." If you are unable to participate during the live webcast, the call will be archived on DURECT's website under Audio Archive in the "Investor Relations" section.
About DURECT Corporation
DURECT is an emerging specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including REMOXY®, POSIDUR™, ELADUR™, and TRANSDUR™-Sufentanil. DURECT's proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs. For more information, please visit www.durect.com.
The DURECT Corporation logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7958
NOTE: POSIDUR™, SABER™, ORADUR®, TRANSDUR™, and ELADUR™ are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners. REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities.